J P Morgan Chase & Co reiterated their buy rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a report released on Monday morning. They currently have a $190.00 price objective on the specialty pharmaceutical company’s stock.

A number of other brokerages have also issued reports on JAZZ. Royal Bank Of Canada set a $210.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a buy rating in a research report on Tuesday, June 27th. Cantor Fitzgerald reaffirmed a buy rating and set a $197.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, June 27th. Janney Montgomery Scott increased their price target on Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the stock a buy rating in a report on Tuesday, July 4th. Deutsche Bank AG reaffirmed a buy rating and set a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, July 4th. Finally, Leerink Swann increased their price target on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the stock a buy rating in a report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $180.96.

Jazz Pharmaceuticals PLC (JAZZ) opened at 148.07 on Monday. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The firm has a market capitalization of $8.89 billion, a PE ratio of 22.81 and a beta of 1.13. The company has a 50 day moving average of $148.82 and a 200 day moving average of $150.52.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). The business had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted $2.67 earnings per share. Analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/21/jazz-pharmaceuticals-plcs-jazz-buy-rating-reiterated-at-j-p-morgan-chase-co.html.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals PLC stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total transaction of $153,520.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction on Monday, July 17th. The stock was sold at an average price of $154.97, for a total value of $30,994.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,717 shares of company stock valued at $1,346,617 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. OppenheimerFunds Inc. raised its stake in shares of Jazz Pharmaceuticals PLC by 54.1% during the 1st quarter. OppenheimerFunds Inc. now owns 150,840 shares of the specialty pharmaceutical company’s stock worth $21,891,000 after buying an additional 52,960 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Jazz Pharmaceuticals PLC by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock worth $218,540,000 after buying an additional 410,031 shares during the last quarter. UBS Group AG raised its stake in shares of Jazz Pharmaceuticals PLC by 17.3% during the 1st quarter. UBS Group AG now owns 338,433 shares of the specialty pharmaceutical company’s stock worth $49,116,000 after buying an additional 50,032 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals PLC during the 1st quarter worth $347,000. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Jazz Pharmaceuticals PLC by 13.8% during the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 17,469 shares of the specialty pharmaceutical company’s stock worth $2,716,000 after buying an additional 2,121 shares during the last quarter. 88.24% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.